

RoslinCT
"Leading global CDMO advancing cell and gene therapies from development to commercialization"
About RoslinCT
RoslinCT provides contract development and manufacturing services for advanced cell and gene therapies. Built on the legacy of the Roslin Institute, which cloned Dolly the Sheep, the company operates purpose-built cGMP facilities in Edinburgh and Massachusetts. Partners access expertise across iPSC development, process sciences, cell banking, and clinical and commercial manufacturing for autologous and allogeneic therapies. The company supports biotech and pharmaceutical partners in navigating regulatory pathways, managing supply chains, and scaling production. With over 400 cGMP batches produced and experience across 20+ cell types, RoslinCT helps translate scientific breakthroughs into treatments for patients with serious diseases.


480
Team Members
2006
Founded
Private Equity
Funding
On-Site
Work Environment
A world where cell and gene therapies are accessible to patients everywhere who need them, transforming lives through advanced medicine delivered at scale with uncompromising quality.
Our mission is to save the lives of patients around the world, by empowering our partners to efficiently progress cell and gene therapies from development to commercialization, as their advanced CDMO partner of choice.